Novogen Limited (NVGN)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
2.08-0.01 (-0.48%)
At close: 4:00 PM EDT
People also watch:
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
Prev Close2.09
Bid0.00 x
Ask0.00 x
Day's Range2.08 - 2.10
52wk Range1.72 - 3.22
1y Target EstN/A
Market Cap35.75M
P/E Ratio (ttm)-4.62
Avg Vol (3m)32,975
Dividend & YieldN/A (N/A)
Earnings DateN/A
Trade prices are not sourced from all markets
  • PR Newswire20 days ago

    Novogen Submits Investigational New Drug (IND) Application to the US FDA For Cantrixil(TM) in Ovarian Cancer

    NASDAQ: NVGN) today announced that it has submitted an Investigational New Drug (IND) application to the United States Food and Drug Administration (FDA) for Cantrixil (TRX-E-002-1) in ovarian cancer. The IND is a detailed regulatory filing which is required to initiate clinical studies in the United States.

  • PR Newswire3 months ago

    Novogen Patent Covering Anisina(TM) Has Proceeded to Grant

    NASDAQ: NVGN) today announced that a patent for the ATM-3500 series had been granted in Australia. The ATM-3500 series includes the investigational agent known as Anisina (ATM-3507). Novogen North America CEO, Dr Andrew Heaton, commented: "This patent provides full protection for Anisina in Australia through to 2035.

  • PR Newswire4 months ago

    Novogen Provides Update On Development Of Cantrixil

    NASDAQ: NVGN) today provided an update on progress regarding the development of Cantrixil (TRXE-002-1), its lead superbenzopyran (SBP) molecule, which is intended for the treatment of ovarian cancer. Cantrixil remains on track to commence clinical trials in the second half of 2016, as the Company has previously indicated. The proposed design of the phase I study has been amended in light of emerging data to focus more specifically on patients with ovarian cancer in order to better understand its effects in the target population, and it is no longer anticipated to be restricted to patients with malignant ascites.